Navigation Links
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
Date:7/23/2013

equency of adverse events was lower in the ARRY-502 group including fewer asthma exacerbations versus the placebo group.  There were no treatment-emergent serious adverse events in patients receiving ARRY-502; all treatment-related adverse events were either mild or moderate in severity.  A total of 15 (11 in the placebo group, 4 in the ARRY-502 group) out of 184 patients discontinued the study early, primarily due to exacerbations of asthma (5 in the placebo group, 1 in the ARRY-502 group).

"There remains a significant need for more convenient, safe and effective therapies for patients with persistent allergic asthma," said Sally Wenzel M.D., Professor of Medicine and Director of the Asthma Institute at the University of Pittsburgh and lead investigator of this trial.
"ARRY-502 is the first oral non-steroidal drug since Singulair® (montelukast) to demonstrate clinically meaningful activity in allergic asthma and represents a potential new oral therapy that may meet these needs."

Ron Squarer, Chief Executive Officer of Array, noted, "With many asthma patients poorly controlled on currently available therapies, a drug targeting a novel, non-overlapping mechanism may present an important new option for millions of patients.  We are seeking an appropriate partner to develop ARRY-502 to its full potential." 

Conference Call InformationArray will hold a conference call on Tuesday, July 23, 2013, at 9:00 a.m. eastern time to discuss these results.  Ron Squarer, Chief Executive Officer, will lead the call.Conference Call InformationDate:Tuesday, July 23, 2013Time:9:00 a.m. eastern timeToll-Free:(888) 771-4371Toll:(847) 585-4405Pass Code:35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout ARRY-502 and CRTh2A
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Enterprise Europe Network - Sport Meets Business: How Entrepreneurs Beat the Recession
3. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
4. Omnetics Meets Increasing Demands of Miniature Electronics Industry with Custom Designed Micro and Nano Cables
5. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
6. Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
7. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
10. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
11. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... 2014 Summary Global Markets Direct,s, ,Arbor ... provides an overview of the Arbor Pharmaceuticals, LLC.,s ... provides comprehensive information on the current therapeutic developmental ... analysis at various stages, therapeutics assessment by drug ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals ... VRX) today announced that the company,s Bridgewater, ... from the U.S. Food and Drug Administration (FDA) relating ... records with regards to Sculptra Aesthetic injectable, which was ... Letter pertains to the management of Valeant,s contract manufacturers (rather ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
... Inc. (OTCQX: DATA), a technology and services company ... trials industry, today announced its participation in the ... will address significant milestones made throughout the pharmaceutical ... technologies are delivering. The EuroMeeting will be held ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... launch of its new formulation of Acetadote ® ... treat acetaminophen poisoning. The proprietary new formulation, which does ... other stabilization or chelating agents, is now stocked at ...
Cached Medicine Technology:DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2New Acetadote® Formulation Now Available in the U.S. 2New Acetadote® Formulation Now Available in the U.S. 3New Acetadote® Formulation Now Available in the U.S. 4
(Date:9/30/2014)... potential for doctors to measure damaging "brain tsunamis" ... moved a step closer to reality, thanks to ... Neuroscience Institute. , The research team, led by ... department of neurosurgery at the UC College of ... spread through an injured brain like tsunami wavescan ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Autism is no stranger to the children of ... is access to clinical services, including reliable diagnosis and ... example, validated for use in Swahili, a major language ... researchers at Brown University and the University of Georgia ... implemented at two sites in the country and found ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... Dynamic health trends, changing consumer ... the Bread Production industry over the past five ... their consumption of a variety of industry goods ... the market for white loaf bread and other ... introducing more nutritious products to attract health-conscious consumers, ...
Breaking Medicine News(10 mins):Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... often forces older adults to give up things ... the ability to exercise and participate in physical ... for Eldercare and Rehabilitation Technology (CERT) are working ... developing and evaluating motion-capture technology that monitors the ...
... than placebo, study finds , , TUESDAY, June 10 (HealthDay News) ... disorder (ADHD) in children, a new study finds. , ... of the American Medical Association , the study compared St. ... 17 and found the herb wasn,t any more effective than ...
... June 10 Sen. Olympia Snowe,(R-ME), member of ... -- S.3101 -- that includes pharmacy-related provisions to ... claims and delay the,implementation of Medicaid reimbursement cuts ... owner of Waltz Pharmacy Inc. in,Camden, ME and ...
... Sen. Gordon Smith,(R-OR), member of the ... includes pharmacy-related provisions to provide prompt,payment of ... delay the,implementation of Medicaid reimbursement cuts for ... National Community Pharmacists,Association (NCPA) past president from ...
... NEW YORK, June 10 Ask any entertainment or ... it,s at. And, while watching,your favorite TV show in ... technology just might., (See video from Siemens ... Biograph HD PET-CT system from Siemens is the world,s ...
... SAN DIEGO and MCLEAN, Va., June 10 SAIC, Inc.,(NYSE: ... William Blair Annual,Growth Stock Conference in Chicago on June 18, ... at 3:10 p.m. Central., A live audio webcast of ... site ( http://investors.saic.com ) and an audio,replay of the event ...
Cached Medicine News:Health News:MU researchers enhancing motion-capture technology to benefit older adults 2Health News:St. John's Wort Doesn't Work for ADHD 2Health News:St. John's Wort Doesn't Work for ADHD 3Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:Oregon Community Pharmacy Owner Thanks Sen. Smith for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:SAIC to Webcast Presentation at William Blair Growth Stock Conference 2
... to match the pace and unique needs ... on Philips strong heritage in patient monitoring, ... has highly flexible screen configuration; an extensive ... such as Event Surveillance, EASI derived 12-lead ...
... of the system is the Nightingale Master Patient ... central monitoring station for the Nightingale Monitoring System. ... Nightingale PPM bedside patient monitors, allowing a clinician ... at once., ,The MPC is a Windows ...
... Signs Monitor 300 Series enhances your productivity ... and after procedures. This easy to use ... readings fast and convenient., ,The Vital ... noninvasive blood pressure monitor with the flexibility ...
... The Welch Allyn Atlas monitor is ... conscious sedation, IV anesthesia procedures, and surgery. ... LED numerics that are visible from across ... to learn how to operate the monitor ...
Medicine Products: